Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Related Articles by Review for PubMed (Select 17940185)

1.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Xing M.

Endocr Rev. 2007 Dec;28(7):742-62. Epub 2007 Oct 16. Review.

PMID:
17940185
2.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

PMID:
20230995
3.

Prognostic utility of BRAF mutation in papillary thyroid cancer.

Xing M.

Mol Cell Endocrinol. 2010 May 28;321(1):86-93. doi: 10.1016/j.mce.2009.10.012. Epub 2009 Oct 31. Review.

4.

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M.

Medicine (Baltimore). 2012 Sep;91(5):274-86. doi: 10.1097/MD.0b013e31826a9c71. Review.

PMID:
22932786
5.

[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].

Lopes JP, Fonseca E.

Acta Med Port. 2011 Dec;24 Suppl 4:855-68. Epub 2011 Dec 31. Review. Portuguese.

6.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Epub 2009 Jun 11. Review. Spanish.

PMID:
19627734
7.

BRAF mutation in thyroid cancer.

Xing M.

Endocr Relat Cancer. 2005 Jun;12(2):245-62. Review.

8.

[BRAF initiating mutations in the papillary thyroid carcinoma].

Rusinek D, Gubała E.

Endokrynol Pol. 2006 Jul-Aug;57(4):438-44. Review. Polish.

PMID:
17006850
9.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

10.

BRAF mutations in papillary thyroid carcinoma.

Wojciechowska K, Lewinski A.

Endocr Regul. 2006 Dec;40(4):129-38. Review.

PMID:
17201587
11.

Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.

Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P.

Curr Med Chem. 2010;17(17):1839-50. Review.

PMID:
20345340
12.

[BRAF gene mutation in thyroid cancer].

Kopczyńska E, Junik R, Tyrakowski T.

Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Review. Polish.

PMID:
16708643
13.

From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.

Albarel F, Conte-Devolx B, Oliver C.

Ann Endocrinol (Paris). 2012 Jun;73(3):155-64. doi: 10.1016/j.ando.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503804
14.

Clinical implications of BRAF mutation in thyroid carcinoma.

Puxeddu E, Durante C, Avenia N, Filetti S, Russo D.

Trends Endocrinol Metab. 2008 May-Jun;19(4):138-45. doi: 10.1016/j.tem.2007.12.003. Epub 2008 Mar 11. Review.

PMID:
18337114
15.

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).

Leonardi GC, Candido S, Carbone M, Raiti F, Colaianni V, Garozzo S, Cinà D, McCubrey JA, Libra M.

Mol Med Rep. 2012 Oct;6(4):687-94. doi: 10.3892/mmr.2012.1016. Epub 2012 Aug 2. Review.

PMID:
22858857
16.

Role of BRAF in thyroid oncogenesis.

Caronia LM, Phay JE, Shah MH.

Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7. Review.

17.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

18.

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Ciampi R, Nikiforov YE.

Endocrinology. 2007 Mar;148(3):936-41. Epub 2006 Aug 31. Review.

PMID:
16946010
19.

Lessons from mouse models of thyroid cancer.

Kim CS, Zhu X.

Thyroid. 2009 Dec;19(12):1317-31. doi: 10.1089/thy.2009.1609. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk